486 related articles for article (PubMed ID: 33098199)
1. The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma.
Wilson HL; D'Agostino RB; Meegalla N; Petro R; Commander S; Topaloglu U; Zhang W; Porosnicu M
Oncologist; 2021 Feb; 26(2):e279-e289. PubMed ID: 33098199
[TBL] [Abstract][Full Text] [Related]
2. Next-generation sequencing (NGS) profiling of matched tumor and circulating tumor DNA (ctDNA) in head and neck squamous cell carcinoma (HNSCC).
Economopoulou P; Spathis A; Kotsantis I; Maratou E; Anastasiou M; Moutafi MK; Kirkasiadou M; Pantazopoulos A; Giannakakou M; Edelstein DL; Sloane H; Fredebohm J; Jones FS; Kyriazoglou A; Gavrielatou N; Foukas P; Panayiotides I; Psyrri A
Oral Oncol; 2023 Apr; 139():106358. PubMed ID: 36871349
[TBL] [Abstract][Full Text] [Related]
3. A comparison between mutational profiles in tumour tissue DNA and circulating tumour DNA in head and neck squamous cell carcinoma - A systematic review.
Huang X; Leo P; Jones L; Duijf PHG; Hartel G; Kenny L; Vasani S; Punyadeera C
Mutat Res Rev Mutat Res; 2024; 793():108477. PubMed ID: 37977279
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumour DNA alterations: emerging biomarker in head and neck squamous cell carcinoma.
Huang X; Duijf PHG; Sriram S; Perera G; Vasani S; Kenny L; Leo P; Punyadeera C
J Biomed Sci; 2023 Aug; 30(1):65. PubMed ID: 37559138
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
[TBL] [Abstract][Full Text] [Related]
6. Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic head and neck squamous cell carcinoma.
Galot R; van Marcke C; Helaers R; Mendola A; Goebbels RM; Caignet X; Ambroise J; Wittouck K; Vikkula M; Limaye N; Machiels JH
Oral Oncol; 2020 May; 104():104631. PubMed ID: 32169746
[TBL] [Abstract][Full Text] [Related]
7. Mutated
Kampel L; Feldstein S; Tsuriel S; Hannes V; Carmel Neiderman NN; Horowitz G; Warshavsky A; Leider-Trejo L; Hershkovitz D; Muhanna N
Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759818
[TBL] [Abstract][Full Text] [Related]
8. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
9. The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer.
Cai J; Jiang H; Li S; Yan X; Wang M; Li N; Zhu C; Dong H; Wang D; Xu Y; Xie H; Wu S; Lou J; Zhao J; Li Q
Front Oncol; 2021; 11():751106. PubMed ID: 35273907
[TBL] [Abstract][Full Text] [Related]
10. The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.
Giacomini P; Valenti F; Allegretti M; Pallocca M; De Nicola F; Ciuffreda L; Fanciulli M; Scalera S; Buglioni S; Melucci E; Casini B; Carosi M; Pescarmona E; Giordani E; Sperati F; Jannitti N; Betti M; Maugeri-Saccà M; Cecere FL; Villani V; Pace A; Appetecchia M; Vici P; Savarese A; Krasniqi E; Ferraresi V; Russillo M; Fabi A; Landi L; Minuti G; Cappuzzo F; Zeuli M; Ciliberto G
J Transl Med; 2023 Oct; 21(1):725. PubMed ID: 37845764
[TBL] [Abstract][Full Text] [Related]
11. Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma.
Lim SM; Cho SH; Hwang IG; Choi JW; Chang H; Ahn MJ; Park KU; Kim JW; Ko YH; Ahn HK; Cho BC; Nam BH; Chun SH; Hong JH; Kwon JH; Choi JG; Kang EJ; Yun T; Lee KW; Kim JH; Kim JS; Lee HW; Kim MK; Jung D; Kim JE; Keam B; Yun HJ; Kim S; Kim HR
Cancer Res Treat; 2019 Jan; 51(1):300-312. PubMed ID: 29747488
[TBL] [Abstract][Full Text] [Related]
12. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumour DNA alterations as biomarkers for head and neck cancer: a systematic review.
Pall AH; Jakobsen KK; Grønhøj C; von Buchwald C
Acta Oncol; 2020 Jul; 59(7):845-850. PubMed ID: 32223478
[No Abstract] [Full Text] [Related]
14. Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma.
Kogo R; Manako T; Iwaya T; Nishizuka S; Hiraki H; Sasaki Y; Idogawa M; Tokino T; Koide A; Komune N; Yasumatsu R; Nakagawa T
Cancer Med; 2022 Nov; 11(21):3960-3968. PubMed ID: 35352507
[TBL] [Abstract][Full Text] [Related]
15. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
16. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of DNA Repair Gene Mutations in Blood and Tumor Tissue and Impact on Prognosis and Treatment in HNSCC.
Burcher KM; Faucheux AT; Lantz JW; Wilson HL; Abreu A; Salafian K; Patel MJ; Song AH; Petro RM; Lycan T; Furdui CM; Topaloglu U; D'Agostino RB; Zhang W; Porosnicu M
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34206538
[TBL] [Abstract][Full Text] [Related]
18. Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma.
Nazha B; Zhuang TZ; Dada HI; Drusbosky LM; Brown JT; Ravindranathan D; Carthon BC; Kucuk O; Goldman J; Master VA; Bilen MA
Oncologist; 2022 Jun; 27(6):462-468. PubMed ID: 35462410
[TBL] [Abstract][Full Text] [Related]
19. Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
Zhang R; Zang J; Xie F; Zhang Y; Wang Y; Jing Y; Zhang Y; Chen Z; Shahatiaili A; Cai MC; Zhao Z; Du P; Jia S; Zhuang G; Chen H
J Urol; 2021 Oct; 206(4):873-884. PubMed ID: 34061567
[TBL] [Abstract][Full Text] [Related]
20. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.
Chae YK; Davis AA; Jain S; Santa-Maria C; Flaum L; Beaubier N; Platanias LC; Gradishar W; Giles FJ; Cristofanilli M
Mol Cancer Ther; 2017 Jul; 16(7):1412-1420. PubMed ID: 28446639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]